ASCO Annual Meeting

Enhertu Fulfills ‘Big Unmet Need’ for Patients with HER2-Low Metastatic Breast Cancer

June 7th 2022, 3:00pm

Article

The findings of the study show that Enhertu should be a new standard of care for patients with HER2-low metastatic breast cancer, according to an expert at Memorial Sloan Kettering Cancer Center.

Adding Darzalex to Popular Multiple Myeloma Treatment Regimen May Lead to Durable Responses

June 7th 2022, 1:00pm

Article

Patients with multiple myeloma were more likely to have no traceable amounts of disease left when Darzalex was added to a treatment regimen of Revlimid, Velcade and dexamethasone.

Addition of Tiragolumab to Tecentriq-Chemo Combo Fails to Boost Outcomes in Small Cell Lung Cancer

June 6th 2022, 9:00pm

Article

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.

Keytruda-Cyramza Combo Bests Standard-of-Care Therapies in Previously Treated Non-Small Cell Lung Cancer

June 6th 2022, 7:00pm

Article

Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.

Early Study Findings Show Novel Drug Elicits Promising Results in Metastatic Breast Cancers

June 6th 2022, 3:00pm

Article

At a follow-up of more than two years, treatment with a novel drug produced meaningful results in a group of patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

SOT101 With or Without Keytruda Shows Promise, Safety in Treating Advanced Solid Tumors

June 6th 2022, 1:00pm

Article

The investigational agent SOT101 was safe and tolerable when given alone and in combination with Keytruda for patients with solid tumors.

Calquence-Based Regimens Continue to Elicit Better Results Than Gazyva Plus Chemotherapy in Untreated Chronic Lymphocytic Leukemia

June 5th 2022, 10:00pm

Article

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

Trodelvy Reduces Risk of Disease Progression in Certain Patients With Metastatic Breast Cancer

June 5th 2022, 5:15pm

Article

Treatment with Trodelvy resulted in slight survival improvements, when compared with standard of care chemotherapy regimens, in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Lenvima Plus Keytruda May Become Next Standard-of-Care Treatment Option for Advanced Kidney Cancer

June 5th 2022, 3:30pm

Article

Treatment with Lenvima plus Keytruda resulted in a 50% decrease in risk of disease progression or death compared with Sutent in patients with advanced kidney cancer.

Adcetris Plus Chemo ‘Potentially Cured’ Some Patients With Hodgkin Lymphoma

June 5th 2022, 1:00pm

Article

Adcetris plus doxorubicin, vinblastine and dacarbazine is the first regimen to improve overall survival compared to the current standard of care for patients with advanced-stage classical Hodgkin lymphoma.